MATTHEW BZDYK: Open Payments
NPI 1528843182 · GLENDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,319 in 62 payments from 19 companies in 2025. Trend: 2023 $0 · 2024 $1,004 · 2025 $1,319
Food & beverage: $1,319
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 10 | $265 |
| ABBVIE INC. | 13 | $213 |
| Ardelyx, Inc. | 6 | $146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $100 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $94 |
| Ipsen Biopharmaceuticals, Inc | 4 | $87 |
| Madrigal Pharmaceuticals | 3 | $85 |
| Aimmune Therapeutics, Inc. | 3 | $51 |
| Lilly USA, LLC | 2 | $49 |
| Gilead Sciences, Inc. | 2 | $34 |
Products named: TREMFYA, IBSRELA, RINVOQ, ENTYVIO, XIFAXAN, IQIRVO, REZDIFFRA, LINZESS.
Industry payments across AZ — which companies pay providers there.
